Today around half of the world's population live in areas where there is a risk of dengue virus (DENV) infection. It is known that at least 100 countries in Asia, the Pacific, the Americas, Africa, and the Caribbean are endemic for DENV. It is estimated that approximately 400 million infections occur annually, including 2 million severe dengue disease cases and 21,000 deaths. However, no approved antiviral therapies or vaccines are available against DENV (1) . There are 4 different serotypes DENV (DENV1-4), all classified within the family Flaviviridae, genus Flavivirus. Although the serotypes have cross reactivity in serological tests they do not produce cross immunity. The main route of virus transmission to humans is the bite of infected Aedes mosquitoes, however, there are other non-vector-borne modes of transmission, which include mothers to fetus transmission, transfusion-related transmission and laboratory mishandle of blood specimen. The incubation period is 5 to 7 days on average but could range from 3 to 12 days. The DENV infection is usually asymptomatic or causes mild dengue fever (DF); nevertheless, it may lead to a life threatening dengue hemorrhagic fever (DHF) As the director of National Reference Laboratory, his aim is a perfect surveillance for improving health system to control global infectious diseases.
